PRODUCT SPECIFICATION

Product Name	Anti-CDKL2 Biotin conjugate
Product Number	HPA040672B
Gene Description	cyclin-dependent kinase-like 2 (CDC2-related kinase)
Alternative Names	KKIAMRE, P56
Clonality	Polyclonal
Isotype	IgG
Host	Rabbit
Conjugation	Biotin
Antigen Sequence	NLIPRHQELFNKNPVFAGVRLPEIKEREPLERRYPKLSEVVIDLAKKCLH IDPDKRPFCAELLHHDFFQMDGFAERFSQELQLKVQKDARNVSLSKKSQN RKKEKEKDDSLVEERKTLVVQDTNADPK
Purification Method	Affinity purified using the PrEST antigen as affinity ligand
Verified Species Reactivity	Human
Recommended Applications	ICC-IF (Immunofluorescence) - Fixation/Permeabilization: PFA/Triton X-100 - Working concentration: 0.25-2 µg/ml
Characterization Data	Available at atlasantibodies.com/products/HPA040672B
Buffer	40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative.
Concentration	Lot dependent
Storage	Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Notes	Gently mix before use. Optimal concentrations and conditions for each application should be determined by the user.

Product of Sweden. For research use only. Not intended for pharmaceutical development, diagnostic, therapeutic or any in vivo use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB.

Warranty: The products supplied by Atlas Antibodies are warranted to meet stated product specifications and to conform to label descriptions when used and stored properly. Unless otherwise stated, this warranty is limited to one year from date of sales for products used, handled and stored according to Atlas Antibodies AB's instructions. Atlas Antibodies AB's sole liability is limited to replacement of the product or refund of the purchase price. All products are supplied for research use only. They are not intended for medicinal, diagnostic or therapeutic use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB Rev. December 2012.